Introduction: Rivaroxaban is a novel direct-acting oral anticoagulant (DOAC) that is used both for the treatment and prevention of thromboembolic diseases. Due to the mechanism of action; the most common side effect can be seen with bleeding. Here we report that a patient with deep vein thrombosis of the lower limbs who presented Henoch Scholein Purpura while taking rivaroxaban. Clinical case: Female patient of the VII decade of life, was administered rivaroxaban, after intolerance to warfarin. On day 4 of the first week of treatment, the patient was admitted to the emergency department with bleeding from the oral mucosa and petechial spots. The patient was diagnosed with Henoch Scholein Purpura due to the use of rivaroxaban, after ruling out most of the possibilities. After stopping rivaroxaban treatment, the patient's bleeding symptoms subsided, the symptoms resolved completely, and her petechiae disappeared. The patient is controlled after the omission of the treatment and completely resolved the clinical picture. Conclusion: So far there are very few reports of this type when taking direct oral anticoagulants. In addition to the known side effects of rivaroxaban treatment, it should be noted that thrombocytopenia may also develop. The Naranjo scale of probability of adverse drug reaction calculated was 7 points. (probable cause of the patient's Purpura).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.